Comparative Pharmacology
Head-to-head clinical analysis: BYETTA versus FORTAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYETTA versus FORTAMET.
BYETTA vs FORTAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
None Documented
None Documented
Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing.
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Category C
Category C
Antidiabetic
Antidiabetic